vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Black Hawk Acquisition Corp (BKHA). Click either name above to swap in a different company.
Black Hawk Acquisition Corp is the larger business by last-quarter revenue ($230.6K vs $169.0K, roughly 1.4× Aligos Therapeutics, Inc.).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
ALGS vs BKHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $230.6K |
| Net Profit | — | $-3.8K |
| Gross Margin | — | — |
| Operating Margin | — | -94.5% |
| Net Margin | — | -1.6% |
| Revenue YoY | -72.1% | — |
| Net Profit YoY | 75.8% | -100.5% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $230.6K | ||
| Q3 25 | $741.0K | $494.5K | ||
| Q2 25 | $965.0K | $767.6K | ||
| Q1 25 | $311.0K | $765.9K | ||
| Q4 24 | $606.0K | — | ||
| Q3 24 | $1.3M | $965.5K | ||
| Q2 24 | $1.1M | $668.2K | ||
| Q1 24 | $694.0K | — |
| Q4 25 | — | $-3.8K | ||
| Q3 25 | $-31.5M | $154.4K | ||
| Q2 25 | $-15.9M | $520.5K | ||
| Q1 25 | $43.1M | $658.4K | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | $883.8K | ||
| Q2 24 | $5.1M | $310.9K | ||
| Q1 24 | $-34.9M | — |
| Q4 25 | — | -94.5% | ||
| Q3 25 | -3827.4% | -69.0% | ||
| Q2 25 | -1924.0% | -32.3% | ||
| Q1 25 | -6187.5% | -14.2% | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | -8.8% | ||
| Q2 24 | -2489.5% | -53.8% | ||
| Q1 24 | -3176.7% | — |
| Q4 25 | — | -1.6% | ||
| Q3 25 | -4256.0% | 31.2% | ||
| Q2 25 | -1643.8% | 67.8% | ||
| Q1 25 | 13854.7% | 86.0% | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | 91.5% | ||
| Q2 24 | 477.0% | 46.5% | ||
| Q1 24 | -5023.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | — | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $-5.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $-3.8M |
| Total Assets | $88.5M | $23.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | — | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | — | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | — | ||
| Q1 24 | $112.7M | — |
| Q4 25 | $53.5M | $-3.8M | ||
| Q3 25 | $71.8M | $-3.3M | ||
| Q2 25 | $101.9M | $-2.5M | ||
| Q1 25 | $116.4M | $-2.3M | ||
| Q4 24 | $-29.0M | — | ||
| Q3 24 | $50.1M | $-2.1M | ||
| Q2 24 | $67.2M | $-2.0M | ||
| Q1 24 | $59.8M | — |
| Q4 25 | $88.5M | $23.9M | ||
| Q3 25 | $109.8M | $23.3M | ||
| Q2 25 | $134.7M | $73.5M | ||
| Q1 25 | $150.7M | $72.8M | ||
| Q4 24 | $70.1M | — | ||
| Q3 24 | $88.4M | $71.4M | ||
| Q2 24 | $108.8M | $70.5M | ||
| Q1 24 | $127.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-100.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-100.5K | ||
| Q3 25 | $-24.3M | $-107.9K | ||
| Q2 25 | $-15.5M | $-278.6K | ||
| Q1 25 | $-20.9M | $-163.3K | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $-20.1M | $-42.8K | ||
| Q2 24 | $-19.5M | $-414.2K | ||
| Q1 24 | $-22.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.70× | ||
| Q2 25 | — | -0.54× | ||
| Q1 25 | -0.49× | -0.25× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.05× | ||
| Q2 24 | -3.85× | -1.33× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
